Mental Health

>

Latest News

Investigational Antidepressant BH-200 Shows Benefit in Phase 2b Trial for MDD / Image credit: ©Srdjan/AdobeStock
Investigational Antidepressant BH-200 Shows Benefit in Phase 2b Trial for MDD

August 6th 2025

The vasopressin V1b antagonist reduced depressive symptoms, with greater effects in genetically-selected patients using a precision psychiatry approach.

Maternal Depression Found to Disrupt Emotional Responsiveness, Infant Care: Daily Dose / image credit: ©New Africa/AdobeStock
Maternal Depression Found to Disrupt Emotional Responsiveness, Infant Care: Daily Dose

July 31st 2025

Postpartum Hormonal Contraceptives Up Depression Risk by 50%: Daily Dose / image credit: ©New Africa/AdobeStock
Postpartum Hormonal Contraceptives Up Depression Risk by 50%: Daily Dose

June 4th 2025

PPD Screening, Medicaid Coverage, and Access to Care: A Q&A with Elizabeth Mollard, PhD
PPD Screening, Medicaid Coverage, and Access to Care: A Q&A with Elizabeth Mollard, PhD

May 20th 2025

Untreated Depression, Anxiety Worsen COPD Outcomes: Daily Dose / image credit: ©New Africa/AdobeStock
Untreated Depression, Anxiety Worsen COPD Outcomes: Daily Dose

April 21st 2025

Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.